Geron

Geron ( GERN) develops therapeutic products for cancer that inhibit telomerase. This stock is trading up 3.1% to $1.16 in recent trading.

Today's Range: $1.13-$1.16
52-Week Range: $0.91-$2.99
Volume: 275,000
Three-Month Average Volume: 767,800

>>5 Rocket Stocsk to Buy in June

From a technical perspective, GERN is bouncing higher here right off its 50-day moving average at $1.12 with lighter-than-average volume. This move is quickly pushing shares of GERN within range of triggering a major breakout trade. That trade will hit if GERN manages to take out some near-term overhead resistance levels at $1.20 to $1.22 and then once it clears more resistance at $1.25 with high volume.

Traders should now look for long-biased trades in GERN as long as it's trending above its 50-day at $1.12 or above some more key near-term support at $1.05, and then once it sustains a move or close above those breakout levels with volume that hits near or above 767,800 shares. If that breakout triggers soon, then GERN will set up re-test or possibly take out its next major overhead resistance levels at $1.40 to its 200-day moving average at $1.45. Any high-volume move above $1.45 to $1.51 will then put its next major overhead resistance levels at $1.78 to $1.83 into range for shares of GERN.

Rosetta Genomics

Rosetta Genomics ( ROSG) develops diagnostic tests and therapeutic tools. This stock is trading up 10.2% to $4.02 in recent trading.

Today's Range: $3.73-$4.22
52-Week Range: $3.09-$17.35
Volume: 1.43 million
Three-Month Average Volume: 267,956

>>5 Hated Earnings Stocks That Deserve Your Love

Shares of ROSG are ripping higher today after the company announced plans to expand its U.S. commercial footprint from five sales territories currently to 12 territories beginning in July. The company also reported the successful launch of its new corporate and product branding at the recent American Society of Clinical Oncology Annual Meeting.

From a technical perspective, ROSG is soaring higher her right off its 50-day moving average at $3.74 with heavy upside volume. This move is quickly pushing shares of ROSG within range of triggering a near-term breakout trade. That trade will hit if ROSG manages to take out some near-term overhead resistance at $4.15 with high volume. At last check, ROSG has started to flirt with that breakout since the stock has hit an intraday high of $4.22 and volume is well above its three-month average action of 267,956 shares.

If you liked this article you might like

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Biotech Premarket Movers: Innoviva, Akebia, Geron

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Geron (GERN) Stock Rises on $80 Million Janssen Licensing Deal